Innovating for the invisible ailment: the ASX-listers combatting chronic pain ASX-listed businesses are answering the call for innovation in the chronic pain space, creating new treatments for a condition that impacts more than three million Australians. Millions of people rely on opioids to manage their chronic pain. Imagine living with a persistent, debilitating discomfort for weeks, months, or even years on end. An ailment that impacted your work and livelihood. Unfortunately, this scenario is far from a stretch of the imagination for more than three million Australians who live with some form of chronic pain. Doctors have investigated chronic pain for years, but the recent emergence of long COVID — where those infected with COVID-19 experience symptoms long after their diagnosis — has brought further attention to this space.